

ANMC Adult Urinary Tract Infection Testing Guideline

Urine Culture Appropriate with UTI Symptoms	Urine Culture Indicated in Absence of Symptoms	Urine Culture Not Indicated
<p><u>No Urinary Catheter</u></p> <ul style="list-style-type: none"> Urinary Urgency Urinary Frequency Suprapubic Tenderness Fever and flank pain or costovertebral angle tenderness <p><u>Urine Catheter Present</u></p> <ul style="list-style-type: none"> Fever and Suprapubic Tenderness Fever and flank pain or costovertebral angle tenderness 	<ul style="list-style-type: none"> Suspected Sepsis without clear source Pregnancy at 12-16 weeks gestation Invasive Urologic Procedure in which mucosal bleeding is expected. 	<ul style="list-style-type: none"> Foul Smelling Urine Cloudy Urine Mental Status Changes Alone Pyuria, Positive Leukocyte Esterase, Nitrite, or bacteria on Urinalysis without appropriate symptoms. Fever without UTI symptoms As a test of cure for UTI

Key Points

<u>How to Obtain a Urine Culture</u>	<u>Clinical Pearls</u>	<u>Asymptomatic Bacteriuria (ASB) is common</u>	<u>Pyuria in setting of ASB</u>
<ul style="list-style-type: none"> Midstream urine <ul style="list-style-type: none"> Instruct patient on proper technique if self-collecting In/Out Catheterization If indwelling catheter present, remove before obtaining urine culture 	<ul style="list-style-type: none"> Diagnosis of a UTI starts with having appropriate symptoms Abnormal urinalysis or positive urine culture does not diagnose a UTI in the absence of symptoms Treating asymptomatic bacteriuria can paradoxically increase risk of subsequent UTI Pan-culturing for fever is not best practice 	<ul style="list-style-type: none"> Healthy premenopausal women 1-5% Women 70-90 years old 11-16% Female long-term care residents 25-50% Male long-term care residents 15-50% Females with diabetes 9-29% Males with diabetes 1-11% People on hemodialysis 25% Long term indwelling urinary catheter 100% 	<ul style="list-style-type: none"> Young women 32% Pregnant women 30-70% Women with diabetes 70% Elderly institutionalized patients 90% Dialysis patients 90% Patients with short-term catheters 30-75% Patients with long-term catheters 50-100%

Antimicrobial Stewardship Created/Approved September 2020

ANMC Adult Ambulatory Urinary Tract Infection Treatment Guideline

This guideline is intended for patients who can tolerate oral therapy and **do NOT** require hospitalization.

Severity	This guideline is intended for patients who can tolerate oral therapy and do NOT require hospitalization.			
Category	Asymptomatic Bacteriuria	Acute Cystitis	Acute Pyelonephritis	Complicated UTI / Catheter-Associated UTI (CAUTI)
Symptoms and/or Risk Factors	Isolation of a specific quantity of bacteria in an appropriately collected urine specimen ($\geq 10^5$ cfu/mL or from catheter; $\geq 10^2$ cfu/mL) from an individual WITHOUT signs or symptoms of infection.	<p>General symptoms: acute onset dysuria, frequency or urgency</p> <p><u>Risk factors for resistance</u></p> <ul style="list-style-type: none"> • Antibiotic exposure within 90 days • Hospitalization within 90 days • Presence of invasive device(s) 	Upper UTI is frequently associated with general symptoms PLUS back/flank pain, fever & chills.	<p>Complicated UTI: infection in the presence of an anatomic or functional abnormality (e.g. enlarged prostate, calculi, obstruction, catheter or stent, neurogenic bladder, renal transplant, neutropenia).</p> <p>Lower UTI classically presents with suprapubic pain, increased frequency, and dysuria.</p>
See ANMC Adult Urinary Tract Infection Testing Guideline				
Culture & Susceptibility (C&S) Investigation	Routine C&S is NOT indicated in asymptomatic patients <u>unless</u> screening for pregnancy or urologic procedure with mucosal bleeding.	Routine C&S is NOT indicated <u>unless</u> risk factor(s) for resistance exist; consider if prescribing 2 nd line therapy	<p>Urine C&S are critical in order to optimize treatment. Urine collection from freshly placed catheter or if discontinued, a voided midstream prior to antibiotics.</p> <p><i>**Note: if <u>indwelling catheter</u> or <u>urinary stent</u>, contact lab to identify all species since multiple isolates or "skin flora" may be discarded as contaminants.</i></p>	
Recommended Treatment and Duration	<p><u>Pregnant women:</u></p> <ol style="list-style-type: none"> 1. Cephalexin 500mg BID x 5d 2. Nitrofurantoin 100mg BID x 5d <p><u>Urologic procedure:</u> Direct treatment based on pre-procedure screening C&S.</p> <p>Treatment is NOT appropriate for women (premenopausal, non-pregnant), diabetics, elderly, nursing home residents, spinal cord injury or indwelling urethral catheters.</p>	<p><u>First Line:</u></p> <ol style="list-style-type: none"> 1. Nitrofurantoin 100mg BID x 5d 2. Cephalexin 500mg BID x 7d <p>Fluoroquinolone FDA Safety Alert: <i>Disabling & potentially permanent adverse effects outweigh benefit in cystitis. Only use when no other alternatives exist.</i></p> <ol style="list-style-type: none"> 3. Ciprofloxacin 250mg BID x 3d <p><i>**Note: If STI risk w/ symptoms of urethritis, consider treatment for Chlamydia.</i></p>	<p><u>First Line:</u></p> <p>1 dose of Ceftriaxone 1gm IM/IV or Gentamicin 5mg/kg IM/IV</p> <p><u>PLUS</u> 1 of the following:</p> <ol style="list-style-type: none"> 1. Cephalexin 1gm BID x 14d 2. Levofloxacin 750mg daily x 5d 3. Ciprofloxacin 500mg BID x 7d <p><i>Tailor maintenance therapy to C&S report.</i></p>	<p>Base empiric treatment on prior culture data. Use acute pyelonephritis treatment unless prior culture data available.</p> <p>Duration:</p> <ul style="list-style-type: none"> • Stop antibiotics 3-5 days after either defervescence or elimination of complicating factor (e.g. catheter, stone) • <i>If female and ≤ 65 years of age, a 3-day regimen <u>may be considered</u> for CAUTI with catheter removal.</i> • <i>If CAUTI and NOT severely ill, a 5-day regimen of levofloxacin 750mg may be considered.</i> • Shorter courses (7 days) are reasonable, if symptoms promptly resolve. • Longer courses (10-14 days) if delayed response, regardless if catheterized or not.
<ul style="list-style-type: none"> • Nitrofurantoin is 1st line for most patients <u>without</u> fever. Toxicity is minimized by short course therapy, which can be safe and effective with a CrCl as low as 30mL/min. • 3rd generation cephalosporins (e.g. cefepodoxime) provide no additional coverage for <i>E.coli</i> or <i>K. pneumoniae</i> over cephalexin. • Per ACOG/IDSA, TMP/SMX 1 DS tab BID x 3d may be used during the 2nd and 3rd trimester if needed as an alternative for nitrofurantoin or cephalexin in pregnancy. • <i>E. coli</i> susceptibility to TMP/SMX is <80% and should be avoided as empiric therapy but may be considered if confirmed by C&S for complicated UTI or pyelonephritis (2 week duration). • For ESBL (Extended Spectrum Beta-lactamase) producing organism, treat according to reported susceptibility with nitrofurantoin, TMP/SMX or FQ. If resistant to all tested antibiotics or multiple allergies, consider Infectious Diseases consultation for potential alternatives: (ex. Fosfomycin). ESBL pyelonephritis may require IV carbapenem. • Penicillin allergy? Inquire about onset and severity of symptoms and update patient medical record. Most PCN-allergic patients CAN safely receive cephalosporins. • Antibiotic prophylaxis for most patients with risk factors for recurrent, complicated UTI is NOT recommended. Risk of resistance outweighs the slight reduction in infection rate. • Methenamine salts or cranberry products should NOT be used routinely to reduce CA-bacteriuria or CA-UTI. 				

Antimicrobial Stewardship Program Approved 2017, Updated October 2020

Executive Summary: International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: **CID 2011;52(5):561–564**. Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: **CID 2010; 50:625–663**. IDSA Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria in Adults. **CID 2005; 40:643–54**. 2015 Updated Beers Criteria. IDSA Clinical Practice Guideline for Management of Asymptomatic Bacteriuria. **CID 2019; 68(10):e83–e110**.